Abstract 1495P
Background
Socially isolated patients have a higher early mortality rate across multiple cancers. However, there have been no reports on how social isolation such as solitary life affects the clinical outcomes in advanced non-small cell lung cancer (NSCLC).
Methods
We conducted a retrospective analysis of patients with advanced NSCLC who received systemic therapy at the National Cancer Center (NCC) between January 2021 and December 2023. This study assessed the association between social isolation, such as living alone, and clinical outcomes, including overall survival (OS) and the incidence of serious adverse events (SAE) during systemic treatment. Additionally, we evaluated the transition rates to palliative care, both at home and in palliative care units (PCU), as well as the proportion of in-hospital deaths at our institution.
Results
During the study period, 679 patients initiated systemic treatment for advanced NSCLC. Of these, 119 patients were living alone (alone group) while the remaining 560 were not (non-alone group). The median age was comparable between the alone and non-alone groups (63 vs. 67 years, p=0.20), but the alone group had a higher proportion of females (46.2% vs. 37.5%, p=0.08). Regarding the driver genetic alterations, there was no significant difference between the two groups in the presence of EGFR mutations (36.1% vs. 32.1%, p=0.70) and ALK rearrangement (7.4% vs. 5.3%, p=0.66). Treatment modalities were also comparable between the alone group and non-alone groups for TKI use (44.1% vs. 39.5%, p=0.86). The alone group showed numerically better outcomes in OS and SAE rates than the non-alone group (OS: not reached vs. 50.7 months, p=0.11; and SAE: 10.9% vs. 18.8%, p=0.08). In the alone group, the transition rates to palliative care at home was significantly lower (13.0% vs. 32.0%, p=0.04), and the proportion of in-hospital deaths (NCC or PCU) was higher compared with non-alone group (82.6% vs. 66.7%, p=0.04).
Conclusions
Social isolation such as living alone did not affect the clinical outcomes such as OS and SAE during the systemic treatment in advanced NSCLC patients. However, it did influence the palliative care practices, resulting in a higher rate of hospital deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T.Yoshida.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10